Home › Funds › Checkpoint Capital L.P. › CYTK
Checkpoint Capital L.P. position in CYTK
CYTOKINETICS INC · Health Care
Checkpoint Capital L.P. reported holding 517,278 shares of CYTK (CYTOKINETICS INC) in its Q3 2026 13F filing — a position valued at US$34.1M, representing 7.71% of its reported portfolio and ranking #4 among its reported holdings. Checkpoint Capital L.P. has disclosed CYTK holdings in 10 of the last 12 reported quarters, going back to Q4 2023.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Checkpoint Capital L.P.'s CYTK position evolved
Checkpoint Capital L.P. first disclosed a stake in CYTK in Q4 2023 at 230,000 shares (US$19.2M). The position peaked in Q2 2026 at 475,000 shares, worth US$40.5M. Across 10 filings, Checkpoint Capital L.P. increased the stake 5 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 517,278 shares valued at US$34.1M — an increase of 42,278 shares quarter over quarter.. Notable position changes include a 146% increase in Q3 2024 (shares fell 11% over the following quarter), a 344% increase in Q4 2025 (shares rose 4% over the following quarter), a 164% increase in Q2 2026 (shares fell 23% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 230.00K | $19.20M | New |
| Q1 2024 | 190.00K | $13.32M | Reduce |
| Q2 2024 | 190.00K | $10.29M | Hold |
| Q3 2024 | 466.81K | $24.65M | Add |
| Q4 2024 | 20.00K | $940.80K | Reduce |
| Q3 2025 | 37.59K | $2.07M | New |
| Q4 2025 | 166.82K | $10.60M | Add |
| Q1 2026 | 180.00K | $11.86M | Add |
| Q2 2026 | 475.00K | $40.47M | Add |
| Q3 2026 | 517.28K | $34.09M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CYTK and 13F data
CYTK (CYTOKINETICS INC) is a Health Care company. 43 other funds we track also report a position in CYTK — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.59B), Avoro Capital Advisors LLC (US$425.9M), RTW INVESTMENTS, LP (US$243.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CYTK
- T. Rowe Price Investment Management, Inc. 18.72M sh · $1.59B · Q2 2026
- Avoro Capital Advisors LLC 5.00M sh · $425.95M · Q2 2026
- RTW INVESTMENTS, LP 2.86M sh · $243.81M · Q2 2026
- Polar Capital Holdings Plc 2.25M sh · $191.99M · Q2 2026
- Integral Health Asset Management, LLC 1.60M sh · $136.30M · Q2 2026
- ARMISTICE CAPITAL, LLC 1.20M sh · $102.34M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.16M sh · $98.81M · Q2 2026
- GW&K Investment Management, LLC 1.02M sh · $67.08M · Q3 2026
- Melqart Asset Management (UK) Ltd 767.52K sh · $65.39M · Q2 2026
- Royalty Pharma Sub-Manager, LLC 980.39K sh · $64.62M · Q3 2026
- Foresite Capital Management IV, LLC 714.70K sh · $60.88M · Q2 2026
- Deep Track Capital, LP 700.00K sh · $59.63M · Q2 2026
More on Checkpoint Capital L.P.
FAQ
How long has Checkpoint Capital L.P. held CYTK?
Checkpoint Capital L.P. has disclosed CYTK holdings in 10 of the last 12 reported quarters, going back to Q4 2023.
What is Checkpoint Capital L.P.'s current position in CYTK?
As of Q3 2026, Checkpoint Capital L.P. holds 517.28K shares of CYTK (CYTOKINETICS INC), valued at $34.09M, representing 7.71% of its reported portfolio and ranking #4.
Has Checkpoint Capital L.P. been buying or selling CYTK?
In the latest 13F filing (Q3 2026), Checkpoint Capital L.P. increased its position in CYTK. The position peaked in Q2 2026 at 475.00K shares.
Which other funds hold CYTK?
Other major institutional holders of CYTK include T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, RTW INVESTMENTS, LP, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.